Today: 19 January 2026
Subscribe
Browse Category

Pharma News News 24 October 2025 - 11 November 2025

Merck (MRK) Stock Could Skyrocket: Key Drug Approvals & Analyst Targets Unveiled

Merck (MRK) Rallies on Nov. 11, 2025: FDA Approves New Keytruda Companion Diagnostic; Fresh SITC Combo Data, and Dow Momentum

Published: November 11, 2025 At a glance (today) Market move: MRK helps lead the Dow’s advance By early afternoon Tuesday, Merck & Co. (NYSE: MRK) shares were up about 3.9%, helping lead the Dow Jones Industrial Average higher; Nike and Merck together contributed an estimated ~36 points to the index’s ~386‑point climb at that time. MarketWatch In a separate Data…
11 November 2025
···
Metsera (MTSR) Sinks as Pfizer Seals Revised $10B Buyout; 8‑K Spells Out $65.60 Cash + Up to $20.65 CVR — Nov. 10, 2025

Metsera (MTSR) Sinks as Pfizer Seals Revised $10B Buyout; 8‑K Spells Out $65.60 Cash + Up to $20.65 CVR — Nov. 10, 2025

Shares of Metsera, Inc. (NASDAQ: MTSR) slumped on Monday after the obesity‑drug developer said it will proceed with a sweetened takeover by Pfizer that ends a high‑stakes bidding war with Novo Nordisk. Metsera accepted Pfizer’s revised offer late Friday; Novo dropped out over the weekend. In early U.S. trading today, MTSR fell ~15% as investors recalibrated expectations around the final…
10 November 2025
···
InflaRx (IFRX) pops on positive INF904 Phase 2a results in HS & CSU; Q3 filing shows €44.4M liquidity and runway into 2027 — Nov 10, 2025

InflaRx (IFRX) pops on positive INF904 Phase 2a results in HS & CSU; Q3 filing shows €44.4M liquidity and runway into 2027 — Nov 10, 2025

InflaRx N.V. (NASDAQ: IFRX) surged into today’s session after unveiling topline Phase 2a data for its oral C5aR inhibitor INF904 in hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU), alongside filing its third‑quarter Form 6‑K showing €44.4 million of available funds and a cash runway into 2027. The company also set out next steps: a Phase 2b HS trial targeted…
10 November 2025
···
Bristol‑Myers Squibb (BMY) today: €5B euro‑notes closing, $239M Celgene suit settlement, BioNTech cash flows lift guidance — what to watch on November 9, 2025

Bristol‑Myers Squibb (BMY) today: €5B euro‑notes closing, $239M Celgene suit settlement, BioNTech cash flows lift guidance — what to watch on November 9, 2025

Financing & balance sheet: euro notes + tender offer Bristol‑Myers Squibb priced €5 billion in senior unsecured notes across five tranches — €750M 2030 (2.973%), €1.15B 2033 (3.363%), €1.15B 2038 (3.857%), €750M 2045 (4.289%), and €1.2B 2055 (4.581%) — with closing anticipated Nov. 10, 2025. The notes are guaranteed by Bristol‑Myers Squibb Company. Bristol Myers Squibb News Proceeds, plus about…
9 November 2025
····
Metsera (NASDAQ: MTSR): Pfizer Clinches $10B Deal as Novo Nordisk Bows Out — What to Know Today (Nov. 8, 2025)

Pfizer Clinches $10B Takeover of Metsera as Novo Nordisk Bows Out — Full Terms, Timeline, and What It Means (Nov. 8, 2025)

Metsera (NASDAQ: MTSR) and Pfizer struck an amended deal worth up to $10B after Novo Nordisk exited the bidding. Here are the final terms, key dates, and what investors should watch next. Updated: November 8, 2025 Top takeaways What changed on Nov. 7–8 Friday, Nov. 7: Metsera announced an amended merger agreement with Pfizer at $86.25 per share (comprised of…
8 November 2025
···
Roche’s $3.5B Bet on 89bio (ETNB) – Stock Soars to New Highs as NASH Breakthrough Looms

Roche’s $3.5B Bet on 89bio (ETNB) – Stock Soars to New Highs as NASH Breakthrough Looms

Recent Developments and News (Nov 2025) 89bio has dominated biotech headlines in late 2025 due to Roche’s takeover move. On October 30, 2025, Roche announced it had successfully completed a tender offer for 89bio at $14.50/share + a $6.00 CVR, and would immediately merge 89bio into its subsidiary Roche Investing. By acquiring over 60% of shares in the tender (and securing another…
5 November 2025
··
Prelude Therapeutics (PRLD) Stock’s Wild Ride: 150% Surge, Big Pharma Deal & What’s Next

Prelude Therapeutics (PRLD) Stock’s Wild Ride: 150% Surge, Big Pharma Deal & What’s Next

A Wild Week for PRLD Stock Prelude Therapeutics – a small precision oncology biotech – suddenly became one of the market’s most volatile stocks in early November 2025. On Monday, Nov 3, PRLD shares skyrocketed, at one point gaining over 150%. The stock surged from roughly $1.60 into the $3–4 range, fueled by speculative buzz and unusually heavy trading Rttnews.…
4 November 2025
····
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk’s $9B Shock Bid Snatches US Weight-Loss Biotech from Pfizer – Stocks React Big

Bidding War Ignites for Obesity Biotech Novo’s takeover push marks a sudden escalation in the weight-loss drug wars. The Danish company – maker of Wegovy and Ozempic – broke ranks on Oct. 30 by notifying Metsera’s board of its superior bid Reuters. This move comes just days after the foundation coup at Novo (demanding faster U.S. growth) Reuters, signaling a…
31 October 2025
···
Apellis’ $458M Shocker: FDA Win, Analyst Buzz & 20% Stock Whiplash

Apellis’ $458M Shocker: FDA Win, Analyst Buzz & 20% Stock Whiplash

Blockbuster Quarter Meets Stock Turbulence Apellis Pharmaceuticals, a biotech focused on complement-mediated diseases Gurufocus, delivered standout financial results for the third quarter of 2025 – yet its stock took a beating. The company reported Q3 revenue of $458.6 million, more than doubling from $196.8 M in the same quarter last year Investing. This record top-line was boosted by a one-time $275 M licensing…
30 October 2025
···
Metsera Stock Skyrockets as Pfizer-Novo Clash in $9B Bidding War

Metsera Stock Skyrockets as Pfizer-Novo Clash in $9B Bidding War

Bidding War Sends Metsera Shares Higher Metsera’s share price has been on a roller-coaster amid takeover speculation. In late September, Pfizer agreed to buy Metsera for $47.50 per share in cash (about $4.9B) plus up to $22.50 in contingent payments Sec. Pfizer CEO Albert Bourla said this deal “propels Pfizer into this key therapeutic area” of obesity treatment Sec. Metsera…
30 October 2025
····
Genenta Science Stock Skyrockets on Strategic Gene-Therapy Alliance – Is a $25 Price Target Next?

Genenta Science Stock Skyrockets on Strategic Gene-Therapy Alliance – Is a $25 Price Target Next?

Genenta’s Oct. 24 announcement ignited optimism. According to the official press release, Anemocyte will incorporate Genenta’s clinically validated LVV plasmid DNA platform (originating from Naldini’s research) into its production pipeline Investing. “By making our clinically validated LVV plasmid DNA technology platform available to Anemocyte and its clients, we are contributing to the reliable and scalable development of advanced therapy programs…
24 October 2025
···
Scienture Holdings (SCNX) Stock Skyrockets on FDA Drug Launch – Will the Rally Last?

Scienture Shares Skyrocket 350% on FDA-Approved Drug Launch – What’s Next?

Scienture’s unprecedented Oct. 23 rally was driven by the commercial rollout of Arbli, its first revenue-generating product. The company’s press release on Oct. 23 confirmed that it began sales and shipped first customer orders for Arbli (losartan suspension), immediately triggering the Nasdaq surge Finviz. CEO/co-CEO Narasimhan Mani said the event “represents a major achievement for Scienture” in moving from development…
24 October 2025
····
1 … 6 7 8 9 10

Stock Market Today

  • LVMH Stock Drops 6.46% Ahead of January Earnings Amid Margin Concerns
    January 19, 2026, 9:45 AM EST. LVMH shares (MC.PA) fell 6.46% to €585.30 on Euronext as investors brace for its January 22 earnings report. The luxury giant's profit margins, especially in Asia and travel retail, along with inventory levels, will be closely watched. Trading volume surged to 231,778 shares, reflecting active selling. At current prices, LVMH trades at a price-to-earnings ratio of 27.68 and a dividend yield of about 2.13%. Meyka AI assigns a buy rating with a target price of €676.95, suggesting potential upside. Risks include fluctuating tourist demand and currency impacts. Market participants await management's update for clues on margin resilience and sales growth across Louis Vuitton, Dior, and others before the quarter closes.
Go toTop